EP4493542A4 - C4-CARBONOTHIOATE SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USE - Google Patents

C4-CARBONOTHIOATE SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USE

Info

Publication number
EP4493542A4
EP4493542A4 EP22931275.6A EP22931275A EP4493542A4 EP 4493542 A4 EP4493542 A4 EP 4493542A4 EP 22931275 A EP22931275 A EP 22931275A EP 4493542 A4 EP4493542 A4 EP 4493542A4
Authority
EP
European Patent Office
Prior art keywords
triptamine
carbonothioate
derivatives
substituted
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22931275.6A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4493542A1 (en
Inventor
Jillian M Hagel
Kaveh Matinkhoo
Peter J Facchini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enveric Biosciences Canada Inc
Original Assignee
Enveric Biosciences Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enveric Biosciences Canada Inc filed Critical Enveric Biosciences Canada Inc
Priority claimed from PCT/CA2022/051266 external-priority patent/WO2023173197A1/en
Publication of EP4493542A1 publication Critical patent/EP4493542A1/en
Publication of EP4493542A4 publication Critical patent/EP4493542A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP22931275.6A 2022-03-18 2022-08-22 C4-CARBONOTHIOATE SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USE Pending EP4493542A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263321440P 2022-03-18 2022-03-18
US202263347835P 2022-06-01 2022-06-01
PCT/CA2022/051266 WO2023173197A1 (en) 2022-03-18 2022-08-22 C4-carbonothioate-substituted tryptamine derivatives and methods of using

Publications (2)

Publication Number Publication Date
EP4493542A1 EP4493542A1 (en) 2025-01-22
EP4493542A4 true EP4493542A4 (en) 2026-03-04

Family

ID=93294636

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22931275.6A Pending EP4493542A4 (en) 2022-03-18 2022-08-22 C4-CARBONOTHIOATE SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USE

Country Status (5)

Country Link
US (1) US20250206701A1 (enExample)
EP (1) EP4493542A4 (enExample)
JP (1) JP2025510666A (enExample)
AU (1) AU2022447256A1 (enExample)
CA (1) CA3246231A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4174016B2 (ja) * 2003-07-11 2008-10-29 株式会社ビーエル 競合法によるサイロシン類のイムノクロマトグラフィー検出法及びテストキット
WO2010059711A1 (en) * 2008-11-18 2010-05-27 Wisconsin Alumni Research Foundation Sigma-1 receptor ligands and methods of use
US20210403425A1 (en) * 2020-06-30 2021-12-30 Field Trip Psychedelics Inc. Tryptamine prodrugs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12590065B2 (en) * 2017-04-14 2026-03-31 Zevra Therapeutics, Inc. Levorphanol prodrugs and processes for making and using them
US12616706B2 (en) * 2019-03-07 2026-05-05 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
AU2021328726A1 (en) * 2020-08-21 2023-03-02 Compass Pathfinder Limited Novel psilocin derivatives having prodrug properties

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4174016B2 (ja) * 2003-07-11 2008-10-29 株式会社ビーエル 競合法によるサイロシン類のイムノクロマトグラフィー検出法及びテストキット
WO2010059711A1 (en) * 2008-11-18 2010-05-27 Wisconsin Alumni Research Foundation Sigma-1 receptor ligands and methods of use
US20210403425A1 (en) * 2020-06-30 2021-12-30 Field Trip Psychedelics Inc. Tryptamine prodrugs

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FERRIZ J.M. ET AL: "Prodrug Design of Phenolic Drugs", CURRENT PHARMACEUTICAL DESIGN, vol. 16, no. 18, 1 June 2010 (2010-06-01), NL, pages 2033 - 2052, XP055834786, ISSN: 1381-6128, DOI: 10.2174/138161210791293042 *
JULIA MARC ET AL: "Indoles. XXII. New synthesis of the indole nucleus. Application to psilocine", CHIMICA THERAPEUTICA, vol. 5, no. 4, 1 January 1970 (1970-01-01), pages 279 - 284, XP093353528, ISSN: 0009-4374 *
See also references of WO2023173197A1 *
TIEN L. HUANG ET AL: "Hydrolysis of carbonates, thiocarbonates, carbamates, and carboxylic esters of α-naphthol, β-naphthol, and p-nitrophenol by human, rat, and mouse liver carboxylesterases", PHARMACEUTICAL RESEARCH, vol. 10, no. 5, 1 January 1993 (1993-01-01), Berlin/Heidelberg, pages 639 - 648, XP055313409, ISSN: 0724-8741, DOI: 10.1023/A:1018987111362 *
TROXLER F ET AL: "Abwandlungsprodukte von Psilocybin und Psilocin", HELVETICA CHIMICA ACTA, VERLAG HELVETICA CHIMICA ACTA, HOBOKEN, USA, vol. 42, no. 6, 1 January 1959 (1959-01-01), pages 2073 - 2103, XP002082906, ISSN: 0018-019X, DOI: 10.1002/HLCA.19590420638 *

Also Published As

Publication number Publication date
EP4493542A1 (en) 2025-01-22
AU2022447256A1 (en) 2024-11-07
US20250206701A1 (en) 2025-06-26
CA3246231A1 (en) 2023-09-21
JP2025510666A (ja) 2025-04-15

Similar Documents

Publication Publication Date Title
EP4566674B1 (en) ANTIBODY COMPOSITIONS AND THEIR METHODS OF USE
EP4412606A4 (en) PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
EP4384160A4 (en) HETEROCYCLIC COMPOUNDS AND METHODS OF USE
EP4304567A4 (en) Targeted therapeutic lipid nanoparticles and their methods of use
EP3983386A4 (en) ACSS2 INHIBITORS AND METHODS OF USE THEREOF
EP4522583A4 (en) PI3K ALPHA INHIBITORS AND THEIR METHODS OF USE
EP4208548A4 (en) DUX4 INHIBITORS AND METHODS OF USE
EP4405358A4 (en) FGFR INHIBITORS AND THEIR METHODS OF USE
EP4072436A4 (en) Stapler apparatus and methods for use
EP4399196A4 (en) PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
EP4263868A4 (en) NANONETWORKS AND METHODS OF USE THEREOF
EP4294804C0 (en) PYRIDONE COMPOUNDS AND THEIR METHODS OF USE
EP4110317A4 (en) Kcnt1 inhibitors and methods of use
EP4490208A4 (en) POLYZWITTERIONIC COMPLEXES AND THEIR METHODS OF USE
EP4401764A4 (en) Anti-Siglec-6 antibodies and their methods of use
EP3941909A4 (en) PI4-KINASE INHIBITORS AND METHODS OF USE THEREOF
EP3983400C0 (en) QUINAZOLINYL COMPOUNDS AND METHODS OF USE
EP4465982A4 (en) APOL1 INHIBITORS AND METHODS OF USE
EP4426314A4 (en) PI3K-ALPHA INHIBITORS AND METHODS OF PREPARATION AND USE THEREOF
EP4412617A4 (en) NEW PIKFYVE INHIBITORS AND THEIR METHODS OF USE
EP4423081A4 (en) PAPD5 INHIBITORS AND METHODS OF USE THEREOF
EP4337235A4 (en) ANELLOVECTORS AND METHODS OF USE
EP4472974A4 (en) HETEROCYCLIC COMPOUNDS AND METHODS OF USE
EP4743078A2 (en) APOL1 INHIBITORS AND METHODS OF USE
EP4743079A2 (en) APOL1 INHIBITORS AND THEIR METHODS OF USE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20241018

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20260203

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 209/16 20060101AFI20260128BHEP

Ipc: A61P 25/00 20060101ALI20260128BHEP

Ipc: A61K 31/4045 20060101ALI20260128BHEP